Skip to main content
# Title Research Year
131 NAVELBLINE AND CAPECITABINE (NAVCAP) FOLLOWED EITHER BY NAVCAP OR BY WEEKLY DOCETAXEL IN THE FIRST-LINE TREATMENT OF HER-2/NEU NEGATIVE METASTATIC BREAST CANCER. 2015
132 METRONOMIC CAPECITABINE WITH VINORELBINE AS A SECOND LINE CHEMOTHERAPY IN ADVANCED BREAST CANCER 2015
133 Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma 2015
134 NAVELBLINE AND CAPECITABINE (NAVCAP) FOLLOWED EITHER BY NAVCAP OR BY WEEKLY DOCETAXEL IN THE FIRST-LINE TREATMENT OF HER-2/NEU NEGATIVE METASTATIC BREAST CANCER. 2015
135 Rate of thyroglossal duct remnant visualization
after total thyroidectomy for differentiated thyroid
carcinoma and its impact on clinical outcome of
radioactive iodine (I‑131) ablation
2015
136 Concurrent Radiochemotherapy in Locally Advanced Head and Neck Cancer: Analysis of Treatment Results and Prognostic factors 2015
137 GDP versus DHAP in relapsed and refractory Hodgkin disease 2015
138 NAVELBLINE AND CAPECITABINE (NAVCAP) FOLLOWED EITHER BY NAVCAP OR BY WEEKLY DOCETAXEL IN THE FIRST-LINE TREATMENT OF HER-2/NEU NEGATIVE METASTATIC BREAST CANCER. 2015
139 Concurrent Radiochemotherapy in Locally Advanced Head and Neck Cancer: Analysis of Treatment Results and Prognostic factors 2015
140 GDP versus DHAP in relapsed and refractory Hodgkin disease 2015